Global Oncolytic Virus Therapies Market - GLOBAL:2021

Global Oncolytic Virus Therapies Market - GLOBAL:2021

Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

7.360,00 €

Detalles

Market Report Coverage :
Start Year : 2020 - Forecast Year : 2030 - Start Value : $93.3 Million in 2020 - Forecast Value : $962.0 Million by 2030 - CAGR % : 0.26%
Description :
Market Report Coverage - Oncolytic Virus Therapies

Market Segmentation

• Commercialized Therapies: Imlygic, Oncorine, and RIGVIR
• Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV
• Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)
• Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)

Regional Segmentation

• North America: U.S.
• Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)
• Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)

Growth Drivers

• Increasing Incidence of Cancer
• Rising Number of Clinical Trials
• Increasing Research Funding from National Cancer Institute
• Increasing Adoption of Inorganic Growth Strategies in the Market

Market Challenges

• High Cost of Therapy
• Lack of Therapy-Specific Assays

Market Opportunities

• Opportunities in the Emerging Economies
• Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
• What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
• How is each segment of the market expected to grow during the forecast period 2020-2030?
• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?
• What is the COVID-19 impact on the global oncolytic virus therapies market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
• What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?
• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types:
o Commercialized Therapies
o Pipeline Therapies
o Type of Virus
o Application
o Region

Market Overview

Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.

Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.

Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.

Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.
Countries Covered :
North America
U.S.
Europe
U.K.
Latvia
Georgia
Armenia
Germany
France
Italy
Rest-of-Europe
Asia-Pacific
China
Japan
Rest-of-APAC
Keywords :
Oncolytic Virus Therapies, Solid Tumor, Hematological Malignancies, Cancer Immunotherapy, Oncolytic Virus Therapies Market, Oncolytic Virus Therapies Report, Oncolytic Virus Therapies Industry, Oncolytic Virus Therapies Market Forecast, Oncolytic Virus Therapies Trends, Oncolytic Virus Therapies Products, Oncolytic Virus Therapies Applications, Oncolytic Virus Therapies Technology, Oncolytic Virus Therapies Companies, Oncolytic Virus Therapies Market Analysis, Oncolytic Virus Therapies Industry Analysis, What is Oncolytic Virus Therapies Market, What are Oncolytic Virus Therapies Market, Oncolytic Virus Therapies Market by Commercialized Therapies, Oncolytic Virus Therapies Market by Pipeline Therapies, Oncolytic Virus Therapies Market by Type of Virus, Oncolytic Virus Therapies Market by Application, Oncolytic Virus Therapies Market by Region, North America Oncolytic Virus Therapies Market, Europe Oncolytic Virus Therapies Market, Asia-Pacific Oncolytic Virus Therapies Market
Press Release :
The premium market intelligence report published by BIS Research on the title Global Oncolytic Virus Therapies Market highlights that the market is projected to reach $962.0 million by 2030. The study also highlights that the market is set to witness a CAGR of 26.28% during the forecast period 2020-2030. The global oncolytic virus therapies market is expected to grow at a double-digit compound annual growth rate in the forecast period 2020-2030, aided primarily by the impressive growth in the underlying services market.

The study defines the impact of cancer on a large section of the world’s population. There were around more than 19 million new cancer cases in 2020 around the globe. As the World Health Organization states, the global healthcare expenditure is on course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which is estimated to constitute almost 43% of the global economic burden. Thus, the soaring demand for better treatment outcomes is leading to an ascending need for preventive, precise healthcare and tailored medication. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. These therapies repair, deactivate, or replace dysfunctional genes that cause diseases with the aim of establishing the normal functioning of the body. Around 4,000 diseases have been linked to gene disorders, which affect millions of people across the globe. The development of oncolytic virus therapies represents a new frontier in science with the potential to help many patients. Although the field of gene therapy has experienced significant setbacks and limited success, it is still one of the most promising and active research fields in medicine.

The comprehensive study covers the following:

• Market numbers on micro-segments that are influencing the market?
• More than 70 pipeline products present in the market
• Market share analysis for more than 15 companies
• Application preference data for solid tumors and hematological malignancies
• Detailed global and regional market share analysis including the scrutiny of more than 15 countries??
• Study of data of more than 30 companies

Who should buy this report?

• Oncolytic virus therapies manufacturers, who are planning to invest in one of the large emerging markets
• Companies involved in drugs development from vector-based therapies
• Companies in the services market such as contract research organization
• Companies involved in developing bioinformatics tools for oncology data analysis, visualization, sharing, and storage

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The premium market intelligence by BIS Research, additionally, throws a spotlight on the opportunities existing in the market, including the high scope for adoption of oncolytic virus therapies in emerging nations, increased use of therapies, and provide solutions for one of the chronic diseases.

The application and pricing analysis of the global market includes data analysis on the satisfaction level of different commercialized therapies. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.

To emphasize the dominance of the North America segment in the regional segmentation of global oncolytic virus therapies market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst – BIS Research, states, "North America is the leading contributor in the global oncolytic virus therapies market and contributed approximately 65.56% to the global market value in 2019. This region is anticipated to grow at a CAGR of 26.21% during the forecast period 2020-2030 and continue dominating the global market in 2030. However, the Europe region is expected to grow at an impressive CAGR of 29.69% during the forecast period from 2020 to 2030.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, and Viralytics Ltd.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

How can market intelligence on oncolytic virus therapies add value to an organization’s decision-making process?

• Aid in drug development
• Help in targeting a segment for launching a new drug
• Offer detailed information on the future perspective of the emerging as well as established players
• Offer go-to market strategies for the different source type
• Support in diversifying the product portfolio based on risk and progression of application
• Help in analyzing technological substitutes and compare the specification
• Offer tailor-made solutions based on the throughput of different consumers
• Aid in understanding the technology requirement
• Assist in exploring the newer application
• Support in analyzing the competitors’ funding scenario
• Support in understanding the involvement of government health organizations such as the National Institute of Health (NIH)
• Aid in understanding the new trends in the industry

Insightful Questions Covered to Enable Companies take Strategic Decisions

• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
• What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
• How is each segment of the market expected to grow during the forecast period 2020-2030?
• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?
• What is the COVID-19 impact on the global oncolytic virus therapies market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
• What are the dynamics of various application areas and countries impacting the global oncolytic virus therapies market?
• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types:
• Commercialized Therapies
• Pipeline Therapies
• Type of Virus
• Application
• Region
Companies Mentioned :
Amgen Inc.
DAIICHI SANKYO COMPANY, LIMITED
DNAtrix
Genelux
Oncolytics Biotech, Inc.
PsiOxus Therapeutics
RIGVIR Ltd.
Shanghai Sunway Biotech Co., Ltd.,
SillaJen, Inc.
Sorrento Therapeutics, Inc.
Takara Bio Inc.
Transgene sa
VCNBiosciences
ViroCure
Viralytics Ltd. (Merck & Co., Inc.)
Press Release :
The premium market intelligence report published by BIS Research on the title Global Oncolytic Virus Therapies Market highlights that the market is projected to reach $962.0 million by 2030. The study also highlights that the market is set to witness a CAGR of 26.28% during the forecast period 2020-2030. The global oncolytic virus therapies market is expected to grow at a double-digit compound annual growth rate in the forecast period 2020-2030, aided primarily by the impressive growth in the underlying services market.

The study defines the impact of cancer on a large section of the world’s population. There were around more than 19 million new cancer cases in 2020 around the globe. As the World Health Organization states, the global healthcare expenditure is on course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which is estimated to constitute almost 43% of the global economic burden. Thus, the soaring demand for better treatment outcomes is leading to an ascending need for preventive, precise healthcare and tailored medication. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. These therapies repair, deactivate, or replace dysfunctional genes that cause diseases with the aim of establishing the normal functioning of the body. Around 4,000 diseases have been linked to gene disorders, which affect millions of people across the globe. The development of oncolytic virus therapies represents a new frontier in science with the potential to help many patients. Although the field of gene therapy has experienced significant setbacks and limited success, it is still one of the most promising and active research fields in medicine.

The comprehensive study covers the following:

• Market numbers on micro-segments that are influencing the market?
• More than 70 pipeline products present in the market
• Market share analysis for more than 15 companies
• Application preference data for solid tumors and hematological malignancies
• Detailed global and regional market share analysis including the scrutiny of more than 15 countries??
• Study of data of more than 30 companies

Who should buy this report?

• Oncolytic virus therapies manufacturers, who are planning to invest in one of the large emerging markets
• Companies involved in drugs development from vector-based therapies
• Companies in the services market such as contract research organization
• Companies involved in developing bioinformatics tools for oncology data analysis, visualization, sharing, and storage

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The premium market intelligence by BIS Research, additionally, throws a spotlight on the opportunities existing in the market, including the high scope for adoption of oncolytic virus therapies in emerging nations, increased use of therapies, and provide solutions for one of the chronic diseases.

The application and pricing analysis of the global market includes data analysis on the satisfaction level of different commercialized therapies. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.

To emphasize the dominance of the North America segment in the regional segmentation of global oncolytic virus therapies market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst – BIS Research, states, "North America is the leading contributor in the global oncolytic virus therapies market and contributed approximately 65.56% to the global market value in 2019. This region is anticipated to grow at a CAGR of 26.21% during the forecast period 2020-2030 and continue dominating the global market in 2030. However, the Europe region is expected to grow at an impressive CAGR of 29.69% during the forecast period from 2020 to 2030.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, and Viralytics Ltd.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

How can market intelligence on oncolytic virus therapies add value to an organization’s decision-making process?

• Aid in drug development
• Help in targeting a segment for launching a new drug
• Offer detailed information on the future perspective of the emerging as well as established players
• Offer go-to market strategies for the different source type
• Support in diversifying the product portfolio based on risk and progression of application
• Help in analyzing technological substitutes and compare the specification
• Offer tailor-made solutions based on the throughput of different consumers
• Aid in understanding the technology requirement
• Assist in exploring the newer application
• Support in analyzing the competitors’ funding scenario
• Support in understanding the involvement of government health organizations such as the National Institute of Health (NIH)
• Aid in understanding the new trends in the industry

Insightful Questions Covered to Enable Companies take Strategic Decisions

• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
• What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
• How is each segment of the market expected to grow during the forecast period 2020-2030?
• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?
• What is the COVID-19 impact on the global oncolytic virus therapies market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
• What are the dynamics of various application areas and countries impacting the global oncolytic virus therapies market?
• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types:
• Commercialized Therapies
• Pipeline Therapies
• Type of Virus
• Application
• Region
Headline :
Global Oncolytic Virus Therapies Market to Reach $962.0 Million by 2030
Table of Contents :
Executive Summary
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Oncolytic Virus Therapies Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market
5 Industry Insights
5.1 Overview
5.2 Regulatory Scenario
5.3 Legal Requirements and Framework in the U.S
5.3.1 Clinical Trial Authorization
5.3.2 U.S. FDA Guidelines for BLA Submission
5.4 Legal Requirements and Framework in Europe
5.4.1 EMA Biologics License Application Process
5.4.2 Centralized Procedure
5.4.3 Decentralized Procedure
5.4.4 Mutual-Recognition Procedure
5.5 Legal Requirements and Framework in Asia-Pacific
5.5.1 China
5.5.2 Japan
5.6 Expedited Regulatory Designations Around the World
5.7 Reimbursement Scenario
5.8 Patent Analysis
5.8.1 Patent Filing Trend
6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Increasing Incidence of Cancer
6.3.2 Rising Number of Clinical Trials
6.3.3 Increasing Research Funding from National Cancer Institute
6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market
6.4 Market Restrains
6.4.1 High Cost of Therapy
6.4.2 Lack of Therapy-Specific Assays
6.5 Market Opportunities
6.5.1 Opportunities in the Emerging Economies
6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies
7 Competitive Landscape
7.1 Synergistic Activities
7.2 Business Expansion Activities and Others
7.3 Product Launches and Product Updates
7.4 Mergers and Acquisitions
7.5 Market Share Analysis
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Commercialized Therapy)
8 Oncolytic Virus Therapies: Epidemiology Analysis
9 Global Oncolytic Virus Therapies Market (by Commercialized Therapies), $Million, 2019-2030
9.1 Overview
9.2 Imlygic
9.3 Oncorine
9.4 RIGVIR
10 Global Oncolytic Virus Therapies Market (by Pipeline Therapies), $Million, 2019-2030
10.1 Overview
10.2 Phase I
10.3 Phase II
10.4 Phase III
10.5 Phase IV
11 Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
11.1 Overview
11.2 Genetically Engineered Oncolytic Virus
11.2.1 Herpes Simplex Virus (HSV)
11.2.2 Adenovirus
11.2.3 Vaccinia Virus
11.3 Oncolytic Wild-Type Virus
11.3.1 Reovirus (Respiratory Enteric Orphan Virus)
11.3.2 Newcastle Disease Virus (NDV)
11.3.3 Vesicular Stomatitis Virus (VSV)
12 Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
12.1 Overview
12.2 Solid Tumor
12.2.1 Breast Cancer
12.2.2 Prostate Cancer
12.2.3 Lung Cancer
12.2.4 Glioblastoma
12.2.5 Melanoma
12.2.6 Other Applications
12.3 Hematological Malignancies
12.3.1 Lymphoma
12.3.2 Leukemia
12.3.3 Myeloma
13 Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
13.1 Overview
13.2 North America
13.2.1 U.S.
13.3 Europe
13.3.1 U.K.
13.3.2 Latvia
13.3.3 Georgia
13.3.4 Armenia
13.3.5 Germany
13.3.6 France
13.3.7 Italy
13.3.8 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 Rest-of-APAC
14 Company Profiles
14.1 Overview
14.2 Amgen Inc.
14.2.1 Company Overview
14.2.2 Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market
14.2.3 Financials
14.2.4 Key Insights about Financial Health of the Company
14.2.5 SWOT Analysis
14.3 DAIICHI SANKYO COMPANY, LIMITED
14.3.1 Company Overview
14.3.2 Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 DNAtrix
14.4.1 Company Overview
14.4.2 Role of DNAtrix in the Global Oncolytic Virus Therapies Market
14.4.3 SWOT Analysis
14.5 Genelux
14.5.1 Company Overview
14.5.2 Role of Genelux in the Global Oncolytic Virus Therapies Market
14.5.3 SWOT Analysis
14.6 Oncolytics Biotech, Inc.
14.6.1 Company Overview
14.6.2 Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market
14.6.3 Financials
14.6.4 SWOT Analysis
14.7 PsiOxus Therapeutics
14.7.1 Company Overview
14.7.2 Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market
14.7.3 SWOT Analysis
14.8 RIGVIR Ltd.
14.8.1 Company Overview
14.8.2 Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market
14.8.3 SWOT Analysis
14.9 Shanghai Sunway Biotech Co., Ltd.,
14.9.1 Company Overview
14.9.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market
14.9.3 SWOT Analysis
14.1 SillaJen, Inc.
14.10.1 Company Overview
14.10.2 Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market
14.10.3 SWOT Analysis
14.11 Sorrento Therapeutics, Inc.
14.11.1 Company Overview
14.11.2 Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 Takara Bio Inc.
14.12.1 Company Overview
14.12.2 Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 Transgene sa
14.13.1 Company Overview
14.13.2 Role of Transgene sa in the Global Oncolytic Virus Therapies Market
14.13.3 Financials
14.13.4 SWOT Analysis
14.14 VCNBiosciences
14.14.1 Company Overview
14.14.2 Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market
14.14.3 SWOT Analysis
14.15 ViroCure
14.15.1 Company Overview
14.15.2 Role of ViroCure in the Global Oncolytic Virus Therapies Market
14.15.3 SWOT Analysis
14.16 Viralytics Ltd. (Merck & Co., Inc.)
14.16.1 Company Overview
14.16.2 Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
List of Tables
Table 5.1: Regulatory Scenario Across the World
Table 5.2: Expedited Regulatory Designations Around the World
Table 5.3: Key Market Access Landscape (by Country), January 2019
Table 9.1: Commercialized Therapies
Table 10.1: Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020
Table 10.2: Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020
Table 10.3: Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020
Table 11.1: Key Herpes Simplex Virus (HSV)-Based Oncolytic Therapies
Table 11.2: Key Adenovirus-Based Oncolytic Therapies
Table 11.3: Key Vaccinia Virus-Based Oncolytic Therapies
Table 11.4: Key Reovirus-Based Oncolytic Therapies
Table 13.1: Rest-of-APAC - Pipeline Drugs
List of Figures
Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies Market
Figure 3: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019 Vs. 2030
Figure 4: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019 vs. 2030
Figure 5: Global Oncolytic Virus Therapies Market Snapshot, $Million, 2019 and 2030
Figure 2.1: Global Oncolytic Virus Therapies Market Segmentation
Figure 3.1: Global Oncolytic Virus Therapies Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 4.2: Global Oncolytic Virus Therapies Market: COVID-19 Impact
Figure 5.1: Clinical Trial Authorization for Oncolytic Virus Therapies
Figure 5.2: Steps for Obtaining Marketing Authorization
Figure 5.3: U.S. FDA Expedited Review Programs
Figure 5.4: Regulatory Strategy for Oncolytic Virus Therapies in the U.S.
Figure 5.5: U.S.FDA Review Timeline
Figure 5.6: Regulatory Strategy for Oncolytic Virus Therapies in Europe
Figure 5.7: EMA Review Timeline
Figure 5.9: Overview of PMDA and MLHW Drug Approval Process in Japan
Figure 5.10: Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021
Figure 6.1: Impact Analysis
Figure 6.2: Cancer Cases Projection, 2016-2020
Figure 6.3: Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019
Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 6.5: NCI Fiscal Budget Year-on-Year, 2013-2018
Figure 6.6: Synergistic Activities, 2018-2020
Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
Figure 7.2: Synergistic Activities Share (by Company), January 2018-March 2021
Figure 7.3: Business Expansion Activities Share (by Company), January 2018-March 2021
Figure 7.4: Number of Product Launches (by Company), January 2018-March 2021
Figure 7.5: Mergers and Acquisitions, January 2018-March 2021
Figure 7.6: Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), $Million, 2020
Figure 7.7: Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020
Figure 8.1: Type of Cancer
Figure 8.2: Global Estimated Percent of New Cancer Cases (by Sex), 2030
Figure 8.3: Expected Cancer Cases in the World (by Country), 2030
Figure 8.4: Relative Number of Expected New Cancer Cases (by Country), 2030
Figure 9.1: Global Oncolytic Virus Therapies Market (Imlygic), $Million, 2019-2030
Figure 9.2: Global Oncolytic Virus Therapies Market (Oncorine), $Million, 2019-2030
Figure 9.3: Global Oncolytic Virus Therapies Market (RIGVIR), $Million, 2019-2030
Figure 10.1: Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019
Figure 11.1: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
Figure 11.2: Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), $Million, 2019 and 2030
Figure 11.3: Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), $Million, 2019-2030
Figure 11.4: Global Oncolytic Virus Therapies Market (Adenovirus), $Million, 2019-2030
Figure 11.5: Global Oncolytic Virus Therapies Market (Vaccinia Virus), $Million, 2019-2030
Figure 11.6: Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), $Million, 2019 and 2030
Figure 11.7: Global Oncolytic Virus Therapies Market (Reovirus), $Million, 2019-2030
Figure 11.8: Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), $Million, 2019-2030
Figure 11.9: Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), $Million, 2019-2030
Figure 12.1: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
Figure 12.2: Global Oncolytic Virus Therapies Market (by Solid Tumor), $Million, 2019 and 2030
Figure 12.3: Global Oncolytic Virus Therapies Market (Breast Cancer), $Million, 2019-2030
Figure 12.4: Global Oncolytic Virus Therapies Market (Prostate Cancer), $Million, 2019-2030
Figure 12.5: Global Oncolytic Virus Therapies Market (Lung Cancer), $Million, 2019-2030
Figure 12.6: Global Oncolytic Virus Therapies Market (Glioblastoma), $Million, 2019-2030
Figure 12.7: Global Oncolytic Virus Therapies Market (Melanoma), $Million, 2019-2030
Figure 12.8: Global Oncolytic Virus Therapies Market (Other Applications), $Million, 2019-2030
Figure 12.9: Global Oncolytic Virus Therapies Market (by Haematological Malignancies), $Million, 2019 and 2030
Figure 12.10: Global Oncolytic Virus Therapies Market (Lymphoma), $Million, 2019-2030
Figure 12.11: Global Oncolytic Virus Therapies Market (Leukemia), $Million, 2019-2030
Figure 12.12: Global Oncolytic Virus Therapies Market (Myeloma), $Million, 2019-2030
Figure 13.1: Global Oncolytic Virus Therapies Market (by Region), 2019-2030
Figure 13.2: Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
Figure 13.3: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2019
Figure 13.4: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2030
Figure 13.5: North America Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.6: North America: Market Dynamics
Figure 13.7: U.S. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.8: Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.11: U.K. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.12: Latvia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.13: Georgia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.14: Armenia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.15: Germany Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.16: France Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.17: Italy Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.18: Rest-of-Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.19: Asia-Pacific Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.20: APAC: Market Dynamics
Figure 13.21: APAC Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.22: China Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.23: Japan Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.24: RoAPAC Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Amgen Inc.: Product Portfolio
Figure 14.3: Amgen Inc.: Overall Financials, $Million, 2018-2020
Figure 14.4: Amgen Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.5: Amgen Inc. R&D Expenditure, $Billion, 2018-2020
Figure 14.6: Amgen Inc.: SWOT Analysis
Figure 14.7: DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio
Figure 14.8: DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, $Billion, 2017-2019
Figure 14.9: Amgen Inc. R&D Expenditure, $Billion, 2017-2019
Figure 14.10: DAIICHI SANKYO COMPANY, LIMITED: SWOT Analysis
Figure 14.11: DNAtrix: Product Portfolio
Figure 14.12: DNAtrix: SWOT Analysis
Figure 14.13: Genelux: Product Portfolio
Figure 14.14: Genelux: SWOT Analysis
Figure 14.15: Oncolytics Biotech, Inc.: Product Portfolio
Figure 14.16: Oncolytics Biotech, Inc.: SWOT Analysis
Figure 14.17: PsiOxus Therapeutics: Pipeline Product Portfolio
Figure 14.18: PsiOxus Therapeutics: SWOT Analysis
Figure 14.19: RIGVIR Ltd.: Overall Service Portfolio
Figure 14.20: RIGVIR Ltd.: SWOT Analysis
Figure 14.21: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 14.22: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 14.23: SillaJen, Inc.: Product Portfolio
Figure 14.24: SillaJen, Inc.: SWOT Analysis
Figure 14.25: Sorrento Therapeutics, Inc.: Product Portfolio
Figure 14.26: Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 14.27: Sorrento Therapeutics, Inc. R&D Expenditure, $Million, 2017-2019
Figure 14.28: Sorrento Therapeutics, Inc.: SWOT Analysis
Figure 14.29: Takara Bio Inc.: Product Portfolio
Figure 14.30: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 14.31: Takara Bio Inc.: Revenue (by Segment), $Million, 2017-2019
Figure 14.32: Takara Bio Inc.: Revenue (by Region), $Million, 2017-2019
Figure 14.33: Takara Bio Inc.: R&D Expenditure, 2017-2019
Figure 14.34: Takara Bio Inc.: SWOT Analysis
Figure 14.35: Transgene sa: Product Portfolio
Figure 14.36: Transgene sa: Overall Financials, $Million, 2017-2019
Figure 14.37: Transgene sa: SWOT Analysis
Figure 14.38: VCNBiosciences: Pipeline Product Portfolio
Figure 14.39: VCNBiosciences: SWOT Analysis
Figure 14.40: ViroCure: Product Portfolio
Figure 14.41: ViroCure: SWOT Analysis
Figure 14.42: Viralytics Ltd., (Merck & Co., Inc.): Product Portfolio
Figure 14.43: Merck & Co., Inc.: Overall Financials, $Million, 2018-2020
Figure 14.44: Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 14.45: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.46: Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020
Figure 14.47: Merck & Co., Inc.: SWOT Analysis

Información adicional

Autor BIS Research INC.
Publicado por BISRESEARCH
Tipo de Documento Informe
Número de páginas 179
Palabra clave Global Oncolytic Virus Therapies Market